Literature DB >> 15771963

Attenuation of pain-related behavior in a rat model of trigeminal neuropathic pain by viral-driven enkephalin overproduction in trigeminal ganglion neurons.

Alice Meunier1, Alban Latrémolière, Annie Mauborgne, Sylvie Bourgoin, Valérie Kayser, François Cesselin, Michel Hamon, Michel Pohl.   

Abstract

Trigeminal neuropathic pain represents a real challenge to therapy because commonly used drugs are devoid of real beneficial effect or patients frequently become intolerant or refractory to some of these compounds. In a rat model of trigeminal neuropathic pain, which shares numerous similarities with human trigeminal neuralgia and trigeminal neuropathic pain, we used a genomic herpes simplex virus-derived vector (HSVLatEnk) to examine the possible effect of a local overproduction of proenkephalin A (PA) targeted to the trigeminal primary sensory neurons. Unilateral peripheral inoculation of recombinant vectors on the vibrissal pad territory resulted in an about ninefold increase in proenkephalin A mRNA levels in trigeminal ganglion ipsilateral to the infected side. Transgene-derived met-enkephalin accumulated in numerous nerve cell bodies of trigeminal ganglion and was transported through the sensory nerve fibers located in the infraorbital nerve. Bilateral mechanical hyperresponsiveness, which developed 2 weeks after chronic constrictive injury of the left infraorbital nerve, was significantly attenuated in animals overproducing PA in the trigeminal ganglion ipsilateral to the lesioned infraorbital nerve. This antiallodynic effect was reversed by both the opioid receptor antagonist naloxone and the peripherally acting antagonist naloxone methiodide. Our data demonstrate that the local overproduction of PA-derived peptides in trigeminal ganglion sensory neurons evoked a potent antiallodynic effect through the stimulation of mainly peripherally located opioid receptors and suggest that targeted delivery of endogenous opioids may be of interest for the treatment of some severe forms of neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15771963     DOI: 10.1016/j.ymthe.2004.12.011

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  33 in total

1.  Bone marrow stromal cells produce long-term pain relief in rat models of persistent pain.

Authors:  Wei Guo; Hu Wang; Shiping Zou; Ming Gu; Mineo Watanabe; Feng Wei; Ronald Dubner; George T-J Huang; Ke Ren
Journal:  Stem Cells       Date:  2011-08       Impact factor: 6.277

Review 2.  Viral vector-based gene transfer for treatment of chronic pain.

Authors:  Shuanglin Hao; Marina Mata; David J Fink
Journal:  Int Anesthesiol Clin       Date:  2007

3.  Effects of transgene-mediated endomorphin-2 in inflammatory pain.

Authors:  Shuanglin Hao; Darren Wolfe; Joseph C Glorioso; Marina Mata; David J Fink
Journal:  Eur J Pain       Date:  2008-06-24       Impact factor: 3.931

4.  Effect of naloxone-3-glucuronide and N-methylnaloxone on the motility of the isolated rat colon after morphine.

Authors:  Peter Reber; Rudolf Brenneisen; Beatrice Flogerzi; Catarina Batista; Peter Netzer; Ulrich Scheurer
Journal:  Dig Dis Sci       Date:  2007-01-09       Impact factor: 3.199

5.  Modulating pain in the periphery: gene-based therapies to enhance peripheral opioid analgesia: Bonica lecture, ASRA 2010.

Authors:  Srinivasa N Raja
Journal:  Reg Anesth Pain Med       Date:  2012 Mar-Apr       Impact factor: 6.288

6.  Gene therapy for bladder overactivity and nociception with herpes simplex virus vectors expressing preproenkephalin.

Authors:  Hitoshi Yokoyama; Katsumi Sasaki; Michael E Franks; William F Goins; James R Goss; William C de Groat; Joseph C Glorioso; Michael B Chancellor; Naoki Yoshimura
Journal:  Hum Gene Ther       Date:  2009-01       Impact factor: 5.695

7.  Intrathecal AAV serotype 9-mediated delivery of shRNA against TRPV1 attenuates thermal hyperalgesia in a mouse model of peripheral nerve injury.

Authors:  Takashi Hirai; Mitsuhiro Enomoto; Hidetoshi Kaburagi; Shinichi Sotome; Kie Yoshida-Tanaka; Madoka Ukegawa; Hiroya Kuwahara; Mariko Yamamoto; Mio Tajiri; Haruka Miyata; Yukihiko Hirai; Makoto Tominaga; Kenichi Shinomiya; Hidehiro Mizusawa; Atsushi Okawa; Takanori Yokota
Journal:  Mol Ther       Date:  2013-10-28       Impact factor: 11.454

Review 8.  Applications of gene therapy to the treatment of chronic pain.

Authors:  Marina Mata; Shuanglin Hao; David J Fink
Journal:  Curr Gene Ther       Date:  2008-02       Impact factor: 4.391

Review 9.  Gene therapy directed at the neuroimmune component of chronic pain with particular attention to the role of TNF alpha.

Authors:  Marina Mata; Shuanglin Hao; David J Fink
Journal:  Neurosci Lett       Date:  2008-03-22       Impact factor: 3.046

10.  Peripheral non-viral MIDGE vector-driven delivery of beta-endorphin in inflammatory pain.

Authors:  Halina Machelska; Matthias Schroff; Detlef Oswald; Waltraud Binder; Nicolle Sitte; Shaaban A Mousa; Heike L Rittner; Alexander Brack; Dominika Labuz; Melanie Busch; Burghardt Wittig; Michael Schäfer; Christoph Stein
Journal:  Mol Pain       Date:  2009-12-14       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.